[1] Overall Survival with Osimertinib in Untreated, EGFR-Mutated  Advanced NSCLC. N Engl J Med. 2019 Nov 21.

[2] Gefitinib Alone Versus Gefitinib Plus Chemotherapy for NonSmall-Cell Lung Cancer With Mutated Epidermal Growth Factor  Receptor: NEJ009 Study. J Clin Oncol. 2019 Nov 4:JCO1901488. 

[3]  versus Standard of Care EGFR TKI as First-Line  Treatment in Patients with EGFRm Advanced NSCLC: FLAURA  Asian Subset. J Thorac Oncol. 2019 Jan;14(1):99-106.

[4] Improvement in Overall Survival in a Randomized Study That  Compared Dacomitinib With Gefitinib in Patients With Advanced  Non–Small-Cell Lung Cancer and EGFR Activating Mutations. J  Clin Oncol. 2018 Aug 1;36(22):2244-2250. 

[5] Osimertinib in Untreated EGFR-Mutated Advanced Non-SmallCell Lung Cancer. N Engl J Med. 2018 Jan 11;378(2):113-125.

[6] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive  Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629-640.

[7] Dacomitinib versus gefitinib as first-line treatment for patients with  EGFR-mutation-positive non-small-cell lung cancer (ARCHER  1050): a randomised, open-label, phase 3 trial. Lancet Oncol.  2017 Nov;18(11):1454-1466.

[8] Milestone Analyses of Immune Checkpoint Inhibitors, Targeted  Therapy, and Conventional Therapy in Metastatic Non-Small Cell  Lung Cancer Trials: A Meta-analysis. JAMA Oncol. 2017 Aug 10;3(8):e171029.

[9] Biomarker Analyses and Final Overall Survival Results From a  Phase III, Randomized, Open-Label, First-Line Study of Gefitinib  Versus Carboplatin/Paclitaxel in Clinically Selected Patients With  Advanced Non–Small-Cell Lung Cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20;29(21):2866-74.

责任编辑：MJ

排版编辑：HJ